HDV Screening Study

Universal Screening for Hepatitis Delta Virus (HDV) in Individuals Living with HIV/HBV Coinfection and HBV-related HCC

NCT06889805•Grace Lai Hung Wong

View on ClinicalTrials.gov

Summary

This is a territory-wide cross-sectional study of all individuals living with HIV/HBV coinfection and HBV-related HCC.

Detailed Description

Chronic hepatitis B virus (HBV) infection remains endemic in Hong Kong with an estimated prevalence of 6.2% in the recent Population Health Survey 2020-2022.1 The estimated prevalence of chronic HBV infection among individuals living with HIV is 8%.2 Yet, no data are available concerning the disease burden of hepatitis delta virus (HDV) among individuals living with HIV/HBV coinfection.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Individuals with HIV infection, i.e. anti-HIV or HIV RNA positive; AND
•2. Individuals with chronic hepatitis B, i.e. hepatitis B surface antigen (HBsAg) or HBV DNA positive for two times at least 6 months apart; AND
•3. Aged 18 years old or above.
•4. Written or verbal consent obtained

Exclusion Criteria

•1. Refusal to consent
•2. Age \< 18 years

Locations (1)

The Chinese University of Hong Kong

Hong Kong, Hong Kong

Key Dates

Start Date

February 15, 2025

Primary Completion Date

August 17, 2028

Completion Date

February 17, 2029

Last Updated

March 24, 2025

Enrollment

300

ESTIMATED participants

Conditions

Hepatitis D Virus Infection

Contacts

Angel Chim

CONTACT

+85235054205 angelchim@cuhk.edu.hk